About Aeterna Zentaris
Listed on Nasdaq under the ticker AEZS, Aeterna Zentaris is a specialty pharmaceutical company with a commercial and clinical focus on endocrinology and oncology. Headquartered in Charleston, South Carolina, the company traces its origins to the Canadian biotech Aeterna Laboratories, which merged with the German firm Zentaris GmbH to form its current identity. This transatlantic background informs a development philosophy that blends North American regulatory strategy with European scientific heritage.
The company's most recognised commercial asset is Macrilen (macimorelin), an oral growth hormone deficiency diagnostic approved by the US Food and Drug Administration and the European Medicines Agency. Macimorelin is the first and only orally active ghrelin receptor agonist indicated for the diagnosis of adult growth hormone deficiency, offering clinicians a more convenient alternative to traditional stimulation tests that require intravenous administration.
Beyond its diagnostic franchise, Aeterna Zentaris has historically pursued oncology programmes targeting hormonal cancers, including compounds evaluated in adrenocortical carcinoma and endometrial cancer. The company operates a lean commercial model, partnering with regional distributors and licensing counterparts to extend the reach of its approved diagnostics without maintaining a large direct sales infrastructure.
As a publicly traded entity subject to SEC reporting requirements, Aeterna Zentaris provides regular updates on its financial position, pipeline status, and commercial activities through filings available on the US Securities and Exchange Commission's EDGAR platform and through its corporate investor relations channels.
Further information is available at zentaris.com.
